Genetic analysis of the kinome and phosphatome in cancer

Cellular and Molecular Life Sciences

Volumn 62, Issue 18, 2005, Pages 2092-2099

  Arena, S ^a   Benvenuti, S ^a   Bardelli, A ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

Cancer; Kinase; Mutational analysis; Phosphatase; Phosphorylation

Indexed keywords

PHOSPHATASE; PHOSPHOPROTEIN PHOSPHATASE; PHOSPHOTRANSFERASE; PROTEIN KINASE;

CANCER; CANCER GENETICS; GENETIC ANALYSIS; MULTIGENE FAMILY; MUTATION; PROTEIN PHOSPHORYLATION; REVIEW;

DNA MUTATIONAL ANALYSIS; GENES, NEOPLASM; HOMEOSTASIS; HUMANS; MUTATION; NEOPLASMS; PHOSPHOPROTEIN PHOSPHATASE; PHOSPHORYLATION; PROTEIN KINASES;

EID: 24744435157     PISSN: 1420682X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00018-005-5205-1     Document Type: Review

References (41)

1. Burnett G. and Kennedy E. P. (1954) The enzymatic phosphorylation of proteins. J. Biol. Chem. 211 (2): 969-980
2. Sutherland E.W. Jr and Wosilait W. D. (1955) Inactivation and activation of liver phosphorylase. Nature 175 (4447): 169-170
3. Toker A. (1998) The synthesis and cellular roles of phosphatidylinositol 4,5-bisphosphate. Curr. Opin. Cell Biol. 10 (2): 254-261
4. Saiardi A., Bhandari R., Resnick A. C., Snowman A. M., Snyder S. H. (2004) Phosphorylation of proteins by inositol pyrophosphates. Science 306 (5704): 2101-2105
5. Czernilofsky A. P., Levinson A. D., Varmus H. E., Bishop J. M., Tischer E., Goodman H. M. (1980) Nucleotide sequence of an avian sarcoma virus oncogene (src) and proposed amino acid sequence for gene product. Nature 287 (5779): 198-203
6. Tonks N. K, Diltz C. D, Fischer E. H. (1988) Purification of the major protein-tyrosine-phosphatases of human placenta. J. Biol. Chem. 263 (14): 6722-6730
7. Guan K. L., Haun R. S., Watson S. J., Geahlen R. L., Dixon J. E. (1990) Cloning and expression of a protein-tyrosine-phosphatase. Proc. Natl. Acad. Sci. USA 87 (4): 1501-1505
8. Manning G., Whyte D. B., Martinez R., Hunter T., Sudarsanam S. (2002) The protein kinase complement of the human genome. Science 298 (5600): 1912-1934
9. Zhang Z. Y. (2001) Protein tyrosine phosphatases: prospects for therapeutics. Curr. Opin. Chem. Biol. 5 (4): 416-423
10. Alonso A., Sasin J., Bottini N., Friedberg I., Osterman A., Godzik A. et al. (2004) Protein tyrosine phosphatases in the human genome. Cell 117 (6): 699-711
11. Plowman G. D., Sudarsanam S., Bingham J., Whyte D., Hunter T. (1999) The protein kinases of Caenorhabditis elegans: a model for signal transduction in multicellular organisms. Proc. Natl. Acad. Sci. USA 96 (24): 13603-13610
12. Lyon M. A., Ducruet A. P., Wipf P, Lazo J. S. (2002) Dual-specificity phosphatases as targets for antineoplastic agents. Nat. Rev. Drug Discov. 1 (12): 961-976
13. Vogelstein B., Kinzler K. W. (2004) Cancer genes and the pathways they control. Nat. Med. 10 (8): 789-799
14. Vogelstein B., Kinzler K. W. The multistep nature of cancer. (1993) Trends Genet. 9 (4): 138-141
15. Futreal P. A., Coin L., Marshall M., Down T., Hubbard T., Wooster R. et al. (2004) A census of human cancer genes. Nat. Rev. Cancer 4 (3): 177-183
16. Saglio G., Cilloni D. (2004) Ab1: the prototype of oncogenic fusion proteins. Cell. Mol. Life Sci. 61 (23): 2897-2911
17. Hynes N. E., Lane H. A. (2005) ERBB receptors and cancer: the complexity of targeted inhibitors. Nat. Rev. Cancer 5 (5): 341-354
18. Rubin B. P., Singer S., Tsao C., Duensing A., Lux M. L., Ruiz R. et al. (2001) KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res 61 (22): 8118-8121
19. Parsons R., Simpson L. (2003) PTEN and cancer. Methods Mol. Biol. 222: 147-166
20. Bentires-Alj M., Paez J. G., David F. S., Keilhack H., Halmos B., Naoki K. et al.(2004) Activating mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia. Cancer Res. 64 (24): 8816-8820
21. Davies H., Bignell G. R., Cox C., Stephens P., Edkins S., Clegg S. et al.(2002) Mutations of the BRAF gene in human cancer. Nature 417: 949-954
22. Bardelli A., Parsons D. W., Silliman N., Ptak J., Szabo S., Saha S. et al. (2003) Mutational analysis of the tyrosine kinome in colorectal cancers. Science 300 (5621): 949
23. Tuveson D. A., Weber B. L., Herlyn M. (2003) BRAF as a potential therapeutic target in melanoma and other malignancies. Cancer Cell 4 (2): 95-98
24. Samuels Y., Wang Z., Bardelli A., Silliman N., Ptak J., Szabo S. et al. (2004) High frequency of mutations of the PIK3CA gene in human cancers. Science 304 (5670): 554
25. Wang Z., Shen D., Parsons D. W., Bardelli A., Sager J., Szabo S. et al. (2004) Mutational analysis of the tyrosine phosphatome in colorectal cancers. Science 304 (5674): 1164-1166
26. Bardelli A., Velculescu V. E. (2005) Mutational analysis of gene families in human cancer. Curr. Opin. Genet. Dev. 15 (1): 5-12
27. Rajagopalan H., Bardelli A., Lengauer C., Kinzler K. W., Vogelstein B., Velculescu V. E. (2002) Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature 418 (6901): 934
28. Lynch T. J., Bell D. W., Sordella R., Gurubhagavatula S., Okimoto R. A., Brannigan B. W. et al.(2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350 (21): 2129-2139
29. Paez J. G., Janne P. A., Lee J. C., Tracy S., Greulich H., Gabriel S. et al. (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304 (5676): 1497-1500
30. Pao W., Miller V., Zakowski M., Doherty J., Politi K., Sarkaria I. et al. (2004) EGF receptor gene mutations are common in lung cancers from never smokers and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc. Natl. Acad. Sci. USA 101 (36): 13306-13311
31. Levitzki A., Gazit A., Osherov N., Posner I., Gilon C. (1991) Inhibition of protein-tyrosine kinases by tyrphostins. Methods Enzymol. 201: 347-361
32. Druker B. J., Tamura S., Buchdunger E., Ohno S., Segal G. M., Fanning S. et al. (1996) Effects of a selective inhibitor of the Ab1 tyrosine kinase on the growth of Bcr-Ab1 positive cells. Nat. Med. 2 (5): 561-566
33. Shah N. P., Sawyers C. L. (2003) Mechanisms of resistance to STI571 in Philadelphia chromosome-associated leukemias. Oncogene 22 (47): 7389-7395
34. Gambacorti-Passerini C. B., Gunby R. H., Piazza R., Galietta A., Rostagno R., Scapozza L. (2003) Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias. Lancet Oncol. 4 (2): 75-85
35. Shah N. P., Tran C., Lee F. Y., Chen P., Norris D., Sawyers C. L. (2004) Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 305 (5682): 399-401
36. Gumireddy K., Baker S. J., Cosenza S. C., John P., Kang A. D., Robell K. A. et al. (2005) A non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistance. Proc. Natl. Acad. Sci. USA 102: 1992-1997
37. Tuveson D. A., Willis N. A., Jacks T., Griffin J. D., Singer S., Fletcher C. D. et al.(2001) STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications. Oncogene 20 (36): 5054-5058
38. Chen H., Isozaki K., Kinoshita K., Ohashi A., Shinomura Y., Matsuzawa Y. et al. (2003) Imatinib inhibits various types of activating mutant kit found in gastrointestinal stromal tumors. Int. J. Cancer 105 (1): 130-135
39. Heinrich M. C., Corless C. L., Demetri G. D., Blanke C. D., von Mehren M., Joensuu H. et al. (2003) Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J. Clin. Oncol. 21 (23): 4342-4349
40. Moroni M., Veronese S., Benvenuti S., Marrapese G., Sartore-Bianchi A., Di Nicolantonio F. et al. (2005) Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol. 6 (5): 279-286
41. Pao W., Miller V. A. (2005) Epidermal growth factor receptor mutations, small-molecule kinase inhibitors and non-small-cell lung cancer: current knowledge and future directions. J. Clin. Oncol. 23 (11): 2556-2568